Grifols SA obtained approval from the U.S. Food and Drug Administration for Erytra Eflexis, its benchtop analyzer for blood testing.

The system uses Grifols' DG Gel technology to ensure that the blood of a transfusion recipient and the donor are compatible.

Erytra Eflexis, which received the European Commission's CE Mark in June 2017, can be used as a stand-alone system or in combination with other Grifols blood typing portfolio solutions, the Spanish healthcare company said.